Iron Deficiency Anemia: Challenges in Diagnosis and Treatment

Abstract

Iron deficiency anemia (IDA) remains the most prevalent hematologic disorder worldwide, presenting significant diagnostic and therapeutic challenges in both resource-limited and high-income clinical settings. This review synthesizes current evidence on the epidemiology, underlying mechanisms, diagnostic approaches, and evolving management of IDA, emphasizing recent advances, guideline updates, and practical clinical implications for healthcare professionals. Special attention is given to the complex interplay of pathophysiology, identification of at-risk populations, differential diagnosis, and the integration of novel therapeutics into clinical practice.

Introduction

Iron deficiency anemia is a multifactorial condition resulting from inadequate iron supply to meet physiological demands, culminating in impaired erythropoiesis and reduced oxygen-carrying capacity. Despite the availability of effective therapies, IDA continues to impose substantial morbidity, especially among vulnerable populations such as children, pregnant women, and patients with chronic comorbidities. The diagnostic pathway is often complicated by overlapping etiologies and the influence of coexisting inflammatory states, necessitating a nuanced, evidence-based approach to assessment and management.

Epidemiology / Disease Burden

Globally, IDA affects approximately 1.2 billion individuals, accounting for a significant proportion of anemia cases in both developing and developed regions. The burden is disproportionately higher in low- and middle-income countries, where dietary insufficiency, parasitic infections, and limited healthcare access prevail. In high-income settings, IDA frequently manifests secondary to chronic blood loss, gastrointestinal diseases, and malabsorption syndromes. The World Health Organization (WHO) estimates that over 40% of children under five and 30% of women of reproductive age are affected by IDA, with far-reaching consequences for neurodevelopment, pregnancy outcomes, work productivity, and overall quality of life.

Pathophysiology

Iron is an essential micronutrient required for hemoglobin synthesis, cellular respiration, and myriad enzymatic reactions. IDA typically develops through one or more mechanisms: decreased dietary intake, impaired absorption (e.g., celiac disease, bariatric surgery), increased physiological demands (e.g., pregnancy, adolescence), or chronic blood loss (e.g., menorrhagia, gastrointestinal bleeding). The body responds with upregulation of intestinal iron absorption and mobilization of iron stores; however, persistent negative balance ultimately depletes ferritin and impairs erythroid precursor proliferation. Additionally, inflammatory cytokines (notably hepcidin) can paradoxically reduce iron availability despite adequate stores, complicating the clinical picture in chronic disease settings.

Risk Factors

Key risk factors for IDA include female gender (due to menstruation and pregnancy), infancy and adolescence (periods of rapid growth), low socioeconomic status, vegetarian or vegan diets, chronic gastrointestinal disorders, use of nonsteroidal anti-inflammatory drugs (NSAIDs), and conditions causing occult or overt blood loss. Elderly patients, those with malignancy, and individuals with chronic kidney disease (CKD) are also at heightened risk, often encountering overlapping mechanisms such as reduced erythropoietin production and inflammation-driven sequestration.

Clinical Features

The clinical manifestation of IDA is variable and often insidious. Common symptoms include fatigue, pallor, exertional dyspnea, palpitations, and reduced exercise tolerance. Severe or prolonged anemia may lead to glossitis, angular cheilitis, koilonychia, and, in rare cases, pica or restless legs syndrome. In children and adolescents, cognitive impairment and developmental delays can occur. Signs such as conjunctival pallor, tachycardia, and systolic flow murmurs are observed on physical examination in moderate to severe cases.

Diagnosis

Diagnosis of IDA is based on a combination of clinical assessment and laboratory evaluation. Initial tests include complete blood count (CBC), revealing microcytic, hypochromic anemia; reduced mean corpuscular volume (MCV); and low mean corpuscular hemoglobin (MCH). Biochemical markers—serum ferritin, serum iron, transferrin saturation (TSAT), and total iron-binding capacity (TIBC)—are critical for confirming iron deficiency. Ferritin is the most sensitive and specific marker; however, it is an acute-phase reactant and may be elevated in inflammatory states, masking underlying deficiency. In such cases, soluble transferrin receptor (sTfR) and reticulocyte hemoglobin content (CHr) may provide additional diagnostic clarity. Evaluation for underlying etiology, particularly sources of chronic blood loss, is crucial and may necessitate gastrointestinal endoscopy, gynecologic assessment, or stool occult blood testing.

Treatment & Management

The cornerstone of IDA management is iron repletion alongside identification and correction of the underlying cause. Oral iron therapy (typically ferrous sulfate, gluconate, or fumarate) remains first-line, administered with attention to dosing strategies (alternate-day dosing may enhance absorption and tolerability). Gastrointestinal side effects—nausea, constipation, abdominal pain—are frequent and often compromise adherence. Parenteral iron formulations (e.g., ferric carboxymaltose, iron sucrose) are indicated in cases of malabsorption, intolerance to oral therapy, or severe anemia requiring rapid correction. Red blood cell transfusion is reserved for life-threatening anemia or impending cardiovascular compromise. Monitoring includes periodic assessment of hemoglobin, reticulocyte response, and iron indices; ongoing evaluation for recurrent or refractory anemia should prompt re-examination for occult sources or alternative diagnoses.

Recent Advances / Emerging Therapies

Recent developments in IDA management include novel intravenous iron preparations with improved safety and dosing profiles, such as ferric derisomaltose and low-molecular-weight iron dextran. Oral heme iron polypeptides and liposomal iron formulations are under investigation for enhanced bioavailability and gastrointestinal tolerability. Hepcidin antagonists and agents targeting iron regulatory pathways represent promising therapeutic avenues, particularly for anemia of chronic disease. Advances in point-of-care diagnostics—such as rapid ferritin and sTfR assays—are enhancing diagnostic accuracy in primary care and resource-limited settings.

Guideline Recommendations

Professional guidelines from organizations such as the WHO, British Society for Haematology, and American Society of Hematology emphasize a stepwise approach: confirm iron deficiency with laboratory indices, identify and treat underlying causes, initiate iron supplementation, and monitor for response. Inflammatory or chronic disease settings, non-traditional markers (e.g., sTfR, CHr) should be utilized. For pregnant women and children, routine screening and prophylactic supplementation in high-risk settings are recommended. Intravenous iron is preferred in cases of intolerance, malabsorption, or severe deficiency. Refractory cases warrant referral to a hematologist for further evaluation.

Conclusion

Iron deficiency anemia is a clinically significant, multifaceted disorder with substantial global impact. Accurate diagnosis requires integration of clinical suspicion with appropriate laboratory and etiologic assessment, while management hinges upon individualized iron repletion and correction of underlying causes. Emerging therapies and diagnostic modalities hold promise for improved patient outcomes and streamlined care pathways. Ongoing research and adherence to evidence-based guidelines are essential to optimizing the diagnosis and treatment of IDA in diverse clinical populations.